GlassScriptPhysician profile
David N Lopez
NPI 1760418867
$23,998.67
in general payments reported to CMS, 2019-2025
53 companies · $2,458 in 2025
The $2,458 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,156 · 2020: $3,414 · 2021: $3,790 · 2022: $4,247 · 2023: $2,802 · 2024: $3,131 · 2025: $2,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,391.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,303.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,788.63 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $2,764.74 | 2019-2025 | |
| Amgen INC. | $2,118.16 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $1,246.20 | 2019-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $1,240.91 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $1,105.91 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Glaxosmithkline, LLC. | $976.42 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $973.21 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $791.13 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Amarin Pharma, INC. | $627.76 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $616.16 | 2019-2024 | Xarelto |
| Sunovion Pharmaceuticals INC. | $500.10 | 2019-2021 | |
| Eisai INC. | $451.39 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $424.00 | 2019-2025 | Trintellix |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.